Efferocytosis is the process by which your body’s immune cells locate, engulf, and digest dead and dying cells before they can leak their contents and trigger inflammation. Roughly ten billion cells die in a healthy adult body every day through normal turnover, and the reason this massive cellular die-off rarely causes problems is that efferocytosis keeps pace, quietly clearing the debris. When this cleanup system falters, the consequences ripple outward into diseases that might seem unrelated on the surface: clogged arteries, autoimmune flare-ups, chronic lung inflammation, and even cancer progression.
How Dead Cells Get Found and Eaten
A cell undergoing programmed death doesn’t just sit quietly and wait. It actively broadcasts two types of signals designed to attract cleanup crews and mark itself for consumption. First, it releases soluble “find-me” signals into the surrounding tissue, small molecules that act like chemical flares drawing nearby immune cells toward the dying cell. Second, it rearranges its own membrane to display “eat-me” signals on its outer surface, flagging itself for ingestion.1PubMed Central. Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums
The most important eat-me signal is a fat molecule called phosphatidylserine. In a living, healthy cell, phosphatidylserine is kept strictly on the inner face of the cell membrane by an enzyme that works like a constant shuffler, flipping it back inward whenever it drifts outward. When a cell begins to die, the machinery reverses: the inward-flipping enzyme shuts down, and a different enzyme called a scramblase rapidly moves phosphatidylserine to the outer surface.2PubMed. An Apoptotic ‘Eat Me’ Signal: Phosphatidylserine Exposure This sudden appearance of phosphatidylserine on the outside of the cell is one of the earliest and most recognizable markers of cell death, and multiple receptor systems on immune cells have evolved to detect it.3PubMed Central. The role of phosphatidylserine recognition receptors in multiple biological functions
Once a macrophage or other phagocyte locks onto a dying cell through one of these receptor systems, it physically engulfs the cell by extending its membrane around it. This step requires extensive remodeling of the phagocyte’s internal scaffolding; the receptor called BAI1, for instance, triggers reorganization of the cell’s structural skeleton to wrap around and internalize its target.4PubMed. Efferocytosis of apoptotic human papillomavirus-positive cervical cancer cells by human primary fibroblasts After engulfment, the dead cell is broken down inside specialized compartments where its components are recycled. This digestive step is itself tightly regulated and feeds back into anti-inflammatory signaling, as the next section describes.
Why Eating Dead Cells Calms Inflammation
Efferocytosis doesn’t just remove debris. It actively reprograms the macrophage that does the eating, shifting it toward an anti-inflammatory state. One key way this happens is through the production of specialized pro-resolving mediators, a family of lipid molecules that actively turn off inflammation rather than simply letting it peter out. When macrophages engulf dead immune cells, their production of these resolving molecules jumps sharply. Resolvin D1, Resolvin D2, and a related mediator called lipoxin B4 all increase several-fold after efferocytosis.5PubMed Central. Macrophage Pro-Resolving Mediators—the When and Where6PubMed Central. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators
This means that every act of cleanup simultaneously sends a “stand down” signal to surrounding immune cells. The more dead cells a macrophage clears, the more it produces these calming signals, creating a feedback loop that pushes the local tissue environment back toward its resting state. Without this loop, even the normal daily death of billions of cells could trigger chronic, low-grade inflammation. The system is elegant because removal and resolution are coupled: you can’t get the anti-inflammatory payoff without doing the cleanup, and you can’t do the cleanup without generating the anti-inflammatory payoff.
There’s an important metabolic dimension too. When a macrophage digests a dead cell, it takes on a load of cholesterol from the dead cell’s membranes. That cholesterol gets processed in the macrophage’s internal recycling compartments and activates a pathway that, among other things, promotes cholesterol export back out of the macrophage. When this export pathway breaks down, cholesterol accumulates inside the macrophage, and the cell’s ability to keep clearing more dead cells declines.7PubMed Central. Lysosomal Cholesterol Hydrolysis Couples Efferocytosis to Anti-Inflammatory Oxysterol Production This connection between cholesterol metabolism and dead-cell clearance turns out to be central to understanding how atherosclerosis develops.
Atherosclerosis and the Necrotic Core Problem
In the arterial walls of people developing heart disease, macrophages gorge on cholesterol-laden particles and become “foam cells.” Early on, when these foam cells die, neighboring macrophages still clear them efficiently, keeping the arterial plaque relatively stable. But as the plaque grows, the macrophages inside it undergo a shift that cripples their ability to perform efferocytosis. Dead cells begin to accumulate faster than they can be removed, and the uncleared corpses rupture and spill their contents, forming what pathologists call a necrotic core. This necrotic core is the dangerous part of a plaque: it drives further inflammation, destabilizes the plaque’s fibrous cap, and ultimately sets the stage for the rupture events that cause heart attacks and strokes.8PubMed Central. Mechanisms and Consequences of Defective Efferocytosis in Atherosclerosis
A key piece of this puzzle involves a receptor on macrophages called MerTK. MerTK is one of the main receptors that macrophages use to recognize and ingest dying cells, and it simultaneously dampens inflammatory signaling. But MerTK has a vulnerability: an enzyme called ADAM17 can clip it from the cell surface, releasing a soluble fragment that floats free in the tissue. This clipped fragment doesn’t just render the macrophage less effective at cleanup; the soluble piece can act as a decoy, soaking up eat-me signals and actively blocking efferocytosis by other nearby cells.9PubMed Central. Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase Cδ, and p38 mitogen-activated protein kinase (MAPK)
Researchers tested how important this cleavage step is by engineering mice whose MerTK receptor was resistant to clipping. These cleavage-resistant mice produced higher levels of pro-resolving mediators, resolved inflammation faster, and suffered less tissue damage in models of acute injury.10PubMed Central. MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation The finding points to MerTK cleavage as a specific molecular chokepoint: block it, and efferocytosis continues working; allow it, and the entire resolution program stalls.
MerTK, Aging, and Senescent Cells
This cleavage problem gets worse with age. Aging tissues accumulate senescent cells, which are cells that have stopped dividing but refuse to die. Instead of dying and being cleared, senescent cells pump out a cocktail of inflammatory molecules that affect their neighbors. Among many other effects, this cocktail promotes MerTK cleavage on nearby macrophages, hobbling their efferocytic capacity. In experiments, macrophages exposed to the secretions of senescent cells showed reduced ability to clear dead cells and increased levels of cleaved MerTK in their surroundings. Macrophages from cleavage-resistant mice were protected from this effect.11PubMed Central. Resolvin D1 promotes efferocytosis in aging by limiting senescent cell-induced MerTK cleavage
The same study found that Resolvin D1, one of the pro-resolving mediators produced during efferocytosis, could counteract this age-related decline. This hints at a vicious cycle in aging tissues: fewer functioning macrophage receptors means less efferocytosis, which means less Resolvin D1 production, which means less protection against further receptor cleavage. Breaking into that cycle at any point could, in principle, restore some of the tissue maintenance capacity that erodes with age.
Autoimmune Disease and Self-Tolerance
Efferocytosis has a purpose beyond simple housekeeping: it prevents the immune system from reacting to the body’s own molecules. When a dead cell is efficiently swallowed and digested inside a macrophage, its internal contents never reach the broader immune surveillance system. But if a dead cell lingers uncleared, it eventually ruptures, spilling proteins and DNA fragments into the tissue. These self-molecules can be mistaken for foreign invaders, priming the adaptive immune system to attack the body’s own tissues.12PubMed Central. The Role of Efferocytosis in Autoimmune Diseases
This mechanism has been most extensively studied in systemic lupus erythematosus, a disease where the immune system generates antibodies against the body’s own DNA and nuclear proteins. Patients with lupus have measurably impaired clearance of dead cells, and the uncleared material fuels the production of the very autoantibodies that define the disease. Rheumatoid arthritis follows a similar logic: inflamed joints accumulate uncleared apoptotic cells, perpetuating the inflammatory cycle. In both cases, the failure is upstream of the autoimmune attack itself. The immune system is doing what it’s designed to do when it encounters foreign-looking material; the problem is that the cleanup system failed to prevent that encounter.
Chronic Lung Diseases
The lungs present a particularly demanding environment for efferocytosis. Every breath exposes the airways to particles, pathogens, and irritants that trigger immune responses and cell death. In healthy lungs, alveolar macrophages (the resident immune cells of the air sacs) are extremely efficient at clearing dead cells and keeping inflammation in check. In several chronic lung conditions, including chronic obstructive pulmonary disease, asthma, and cystic fibrosis, these macrophages show a measurable decline in efferocytic ability, and the airways accumulate abnormally high numbers of uncleared dead cells.13Chest. Translating Basic Research into Clinical Practice Efferocytosis and Lung Disease
Whether this impairment is a cause or a consequence of the disease remains an area of active research, but the hypothesis that restoring efferocytosis could reduce chronic airway inflammation has gained traction. Cigarette smoke, for instance, is known to directly impair macrophage efferocytic function, which could help explain why smokers develop sustained airway inflammation even after they quit. Their macrophages may take time to recover their cleanup ability, leaving dead cells to pile up and perpetuate the cycle.
The Brain’s Version of the Problem
In the brain, the resident immune cells are microglia rather than macrophages, but the principle is the same: they’re responsible for engulfing and digesting dying neurons and other cellular debris. In neurodegenerative diseases like Alzheimer’s, the situation gets complicated. On one hand, timely clearance of dead neurons and amyloid-associated debris is essential. Uncleared cellular remains can fuel pro-inflammatory signaling that accelerates further neuronal loss. On the other hand, overactive or misdirected microglial clearance can go wrong: when microglia begin targeting stressed but still-living neurons, the result is accelerated neuronal death, thinning of brain tissue, and worsening cognitive decline.14The Egyptian Journal of Neurology, Psychiatry and Neurosurgery. Repercussions of microglial efferocytosis on neurodegeneration in Alzheimer’s Disease (AD): a double-edged sword and perplexing factor warranting scrutiny in AD research
This makes the brain a place where efferocytosis is genuinely double-edged in a way that doesn’t quite apply elsewhere. In most tissues, the question is simply “is there enough efferocytosis?” In the brain, the additional question is “is it targeting the right cells?” The distinction between canonical clearance of truly dead cells and non-canonical clearance of stressed-but-viable neurons appears to matter enormously, and researchers are still working out the signals that determine which pathway a microglial cell takes.
Cancer Cells Gaming the System
Cancer introduces an entirely different wrinkle. Tumor cells can exploit the efferocytosis machinery in two opposing directions, both to their advantage.
First, tumor cells protect themselves from being eaten. Healthy cells destined for removal expose eat-me signals; cancer cells overexpress “don’t eat me” signals on their surface. The best known of these is CD47, a protein that acts as a molecular “passport” telling macrophages to back off. Some tumors also upregulate PD-L1 and other anti-phagocytic molecules, stacking multiple layers of immune evasion.15PubMed Central. Don’t eat me/eat me signals as a novel strategy in cancer immunotherapy The result is that macrophages in and around the tumor become less effective at clearing tumor cells that do die, either through natural turnover or in response to treatment.
Second, when tumor-associated macrophages do engage in efferocytosis of dead tumor cells, this can paradoxically help the tumor. The anti-inflammatory reprogramming that normally resolves healthy tissue inflammation instead suppresses anti-tumor immune responses. Macrophages that clear dead tumor cells may shift toward an immunosuppressive state that supports tumor growth and metastasis rather than fighting it.16PubMed Central. Progress of research on the relationship between efferocytosis and tumor In bladder cancer, for example, blocking a surface molecule called CD276 on tumor-associated macrophages was shown to increase expression of molecules involved in antigen presentation, suggesting that CD276-dependent efferocytosis was suppressing the macrophages’ ability to alert the rest of the immune system to the tumor’s presence.17Nature Communications. CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer
This creates a therapeutic paradox. In atherosclerosis, autoimmune disease, and lung disease, the goal is to boost efferocytosis. In cancer, you may need to boost it (to clear tumor cells) and simultaneously block the immunosuppressive consequences, or block the don’t-eat-me signals while preserving the downstream inflammatory response that helps the immune system recognize tumor cells as threats.
Non-Professional Phagocytes as Backup
Macrophages are the heavyweights of efferocytosis, but they’re not the only cells that can do it. When tissue damage occurs faster than macrophages can arrive, neighboring cells that aren’t normally thought of as immune cells step in. Fibroblasts, epithelial cells, and other “non-professional” phagocytes can recognize and engulf dying neighbors, providing an initial wave of cleanup before macrophages migrate to the scene.18Scientific Reports. Non-professional phagocytosis: a general feature of normal tissue cells In tissues where macrophages are sparse or where acute damage occurs suddenly, this backup system may be the first line of defense against the inflammatory consequences of uncleared dead cells.
This backup capacity raises interesting questions about tissue engineering and transplantation, where macrophage populations may be absent or depleted. If non-professional phagocytes can be encouraged to take on more of the clearance burden, it could help manage inflammation in grafts and engineered tissues during the period before a normal immune cell population is established.
Therapeutic Strategies in Development
Given how many diseases involve efferocytosis failure, researchers are pursuing several strategies to restore or enhance it. These broadly fall into two categories: removing the brakes that inhibit efferocytosis, and delivering pro-efferocytic signals directly to the sites where clearance has stalled.
The anti-CD47 approach is probably the furthest along in cancer. Antibodies that block CD47, the don’t-eat-me signal on tumor cells, have been shown to enable macrophage phagocytosis of cancer cells and, importantly, to prime an anti-tumor T-cell response as well. The dual effect is significant: the macrophages don’t just eat the tumor cells, they process and present tumor material to the rest of the immune system, amplifying the anti-cancer response beyond what direct phagocytosis alone would achieve.19PubMed Central. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
For atherosclerosis, several nanoparticle-based approaches are under investigation. One team developed a biomimetic nanoparticle coated in macrophage membrane that carries retinoic acid to atherosclerotic plaques. The macrophage membrane coating allows the particle to home to inflamed tissue, while the retinoic acid payload boosts cholesterol export from macrophages. Additionally, a protein on the nanoparticle’s surface blocks the CD47 pathway on dying cells, removing the brakes on efferocytosis at the same time.20Bioactive Materials. Synergistic enhancement of efferocytosis and cholesterol efflux via macrophage biomimetic nanoparticle to attenuate atherosclerosis progression A separate group combined an anti-inflammatory cytokine with a drug that enhances phagocytic activity into a single nanoparticle platform, aiming to simultaneously boost clearance and tamp down the inflammatory environment inside plaques.21ACS Publications. Development of Pro-resolving and Pro-efferocytic Nanoparticles for Atherosclerosis Therapy
A third approach takes the concept even further, engineering CAR macrophages (macrophages fitted with chimeric antigen receptors, similar to CAR-T cell therapy in cancer) and then modifying their surfaces with nanoparticles that activate the cholesterol export pathway. This combination targets the macrophage both at the level of what it recognizes and how efficiently it processes what it eats.22PubMed Central. Enhancing CAR Macrophage Efferocytosis Via Surface Engineered Lipid Nanoparticles Targeting LXR Signaling
Beyond cardiovascular and cancer applications, biomimetic drug delivery that exploits efferocytosis itself is being developed for inflammatory bowel disease. One platform incorporates membranes from dead red blood cells into liposomes, essentially disguising drug-loaded particles as dead cells so that macrophages preferentially engulf them. In a mouse model of colitis, these particles were selectively taken up by macrophages and delivered an anti-inflammatory drug directly to the cells driving intestinal inflammation.23PubMed Central. Synthetic Biomimetic Liposomes Harness Efferocytosis Machinery for Highly Efficient Macrophages-Targeted Drug Delivery to Alleviate Inflammation The cleverness here is that the delivery system turns the body’s own cleanup process into a targeting mechanism: if you want a drug to reach macrophages at an inflammatory site, package it to look like the thing those macrophages are already programmed to eat.
When Boosting Efferocytosis Could Backfire
Enthusiasm for pro-efferocytic therapy has to be tempered by the contexts where more clearance is not necessarily better. The brain’s vulnerability to overzealous microglial clearance, described earlier, is one example. Cancer is another: broadly enhancing macrophage efferocytosis without addressing the immunosuppressive reprogramming that follows could inadvertently help tumors hide from the immune system more effectively. Even in atherosclerosis, the timing matters. Very early plaques are thought to benefit from efferocytosis, but macrophages in advanced plaques are already overloaded with cholesterol and may not benefit from being asked to eat even more dead cells unless their cholesterol export machinery is simultaneously restored.
The emerging picture is that efferocytosis is not simply good or bad. Its effects depend entirely on which tissue it occurs in, what state the macrophages are in, what they’re clearing, and what signals dominate the local environment afterward. Future therapies will likely need to be tuned not just to increase clearance, but to steer the downstream consequences of clearance in the desired direction, which means boosting it in some tissues, inhibiting specific aspects in others, and managing the metabolic aftermath in all of them.